Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/March/2019, 5.30 am

Epicatechin-3-gallate(ECG)-based antiviral therapy for chikungunya (CHIKV) and Zika (ZIKV) viruses: Epicatechin-3-gallate(ECG), one of the main components of green tea, increases spermidine/spermine N1-acetyltransferase (SAT) expression, depletes spermidine and Spermine levels, and restricts Chikungunya and Zika viruses replication via upregulation of its target gene, 16/March/2019, 5.23 am
March 15, 2019
Repurposing the known anti-hyperglycemic drug Sitagliptin into a stroke medicine: Sitagliptin (brand name: Januvia, Tesavel, Xelevia, and others ), used to bring down high blood glucose levels in Type II diabetes patients, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 16/March/2019, 5.46 am
March 16, 2019
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that LncRNA DGCR5, by decreasing the expression of their target gene, it may increase the expression of Nmnat1. Thereby, it may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; (4) increase insulin sensitivity; and (5) alleviate glaucoma (Fig.1). Thus, LncRNA DGCR5 or its activators either alone or in combination with other drugs, may be used to treat Glaucoma.

Figure 1. Mechanistic insights into how  LncRNA DGCR5 attenuates glaucoma. LncRNA DGCR5, by decreasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

Figure 2. LncRNA DGCR5 functions as an anti-glaucoma agent by increasing NAD+ levels


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does LncRNA DGCR5 increase the levels of NAD+?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/March/2019, 5.30 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.